A head-to-head comparison between technetium-99m-tetrofosmin and technetium-99m-MIBI scintigraphy to evaluate suspicious breast lesions

European Journal of Nuclear Medicine

Volumn 26, Issue 12, 1999, Pages 1553-1559

  Obwegeser, Reinhard ^a   Berghammer, Peter ^b   Rodrigues, Margarida ^b   Granegger, Susanne ^b   Hohlagschwandtner, Maria ^a   Kucera, Herwig ^b   Singer, Christian ^a   Berger, Andreas ^a   Kubista, Ernst ^a   Sinzinger, Helmut ^b  

^a UNIVERSITY OF VIENNA   (Austria)

^b NONE

Author keywords

99mTc MIBI; Breast cancer; Breast tumour diagnosis; Scintimammography; Technetium 99m tetrofosmin

Indexed keywords

METHOXY ISOBUTYL ISONITRILE TECHNETIUM TC 99M; TETROFOSMIN TC 99M;

ADULT; AGED; ARTICLE; BREAST TUMOR; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC IMAGING; DIAGNOSTIC VALUE; FEMALE; HUMAN; IMAGE ANALYSIS; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; RANDOMIZED CONTROLLED TRIAL; SCINTIMAMMOGRAPHY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; FEMALE; HUMANS; MIDDLE AGED; ORGANOPHOSPHORUS COMPOUNDS; ORGANOTECHNETIUM COMPOUNDS; PROSPECTIVE STUDIES; RADIOPHARMACEUTICALS; TECHNETIUM TC 99M SESTAMIBI;

EID: 0033430930     PISSN: 03406997     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002590050494     Document Type: Article

References (47)

1. 1. Hall FM. Screening mammography potential problems on the horizon. N Engl J Med 1986; 314: 53-55.
2. 2. Kopans DB. Positive predictive value of mammography. Am J Roentgenol 1992; 158: 521-526.
3. 3. Maublant JC, Gachon P, Moinis N. Hexakis (2-methoxy-isobutyl-isonitrile) technetium-99m and thallium-201 chloride: uptake and release in cultured myocardial cells. J Nucl Med 1988; 29: 48-53.
4. 4. Baillet GY, Mena IG, Kuperus JH, et al. Simultaneous technetium-99m-MIBI angiography and myocardial perfusion imaging. J Nucl Med 1989; 30: 38-44.
5. 5. Kelly JD, Forster AM, Higley B, et al. Technetium-99m-tetrofosmin as a new radiopharmaceutical for myocardial perfusion imaging. J Nucl Med 1993; 34: 30-38.
6. 6. Waxman A, Ashock G, Kooba A, et al. 99m-Tc-MIBI in evaluation of patients with primary carcinoma of the breast: comparison with thallium-201. Eur J Nucl Med 1992; 17: 761.
7. 7. Palmedo H, Grünwald F, Bender H, et al. Scintimammography with 99m-Tc-MIBI: comparison with mammography and magnetic resonance imaging. Eur J Nucl Med 1996; 23: 940-946.
8. 8. Palmedo H, Schomburg A, Grünwald F, Mallmann P, Krebs D, Biersack HJ. Technetium-99m-MIBI scintimammography for suspicious breast lesions. J Nucl Med 1996; 37: 626-630.
9. 99mTc-MIBI prone breast imaging for the diagnosis of breast cancer. Radiology 1996; 196: 421-426.
10. 99mTc-MIBI breast imaging in breast cancer detection. J Nucl Med 1996; 37: 74.
11. 99mTc-MIBI for breast cancer detection: results of the prospective European multicenter trial. J Nucl Med 1997; 37: 20.
12. 12. Tiling R, Sommer H, Pechmann M, et al. Comparison of 99m-Tc-MIBI scintimammography with contrast-enhanced MRI for diagnosis of breast lesions. J Nucl Med 1997; 38: 58-62.
13. 13. Helbich TH, Becherer A, Trattnig S, et al. Differentiation of benign and malignant breast lesions: MR imaging vs 99m-Tc-MIBI scintimammography. Radiology 1997; 202: 421-429.
14. 14. Mansi L, Rambaldi PF, Procaccini E, et al. Scintimammography with 99m-Tc-tetrofosmin in the diagnosis of breast cancer and lymph node metastases. Eur J Nucl Med 1996; 23: 932-939.
15. 15. Lind P, Gallowitsch HJ, Kogler D, Kresnik E, Mikosch P, Gomez I. 99m-Tc-tetrofosmin scintimammography: a prospective study in primary breast lesions. Nuklearmedizin 1996; 35: 225-229.
16. 16. Vieira MR, Weinholtz JHB. 99m-Tc-tetrofosmin scintigraphy in the diagnosis of breast cancer. Eur J Surg Oncol 1996; 22: 331-334.
17. 17. Mansi L, Rambaldi PF, Cuccurullo V, et al. Diagnostic and prognostic role of 99m-Tc-tetrofosmin in breast cancer. Q J Nucl Med 1997; 41: 239-250.
18. 18. Adalet I, Demirkol MO, Müsümanoglu M, Bozfakioglu Y, Cantez S. 99m-Tc-tetrofosmin scintigraphy in the evaluation of palpable breast masses. Nucl Med Commun 1997; 18: 118-121.
19. 19. Madariaga P, Almoguera I, Alonso A, et al. 99m-Tc-tetrofosmin scintigraphy to evaluate breast lesions. Anticancer Res 1997; 17: 1619-1622.
20. 20. Schillaci O, Scopinaro F, Danieli R, et al. Scintimammography with 99m-Tc-tetrofosmin in suspected breast cancer. Anticancer Res 1997; 17: 1623-1626.
21. 21. Lind P, Umschaden HW, Forsthuber E, et al. Scintimammography using 99m-Tc-tetrofosmin. Acta Med Austr 1997; 24: 50-54.
22. 22. Fenlon HM, Phelan NC, O'Sullivan P, Tierney S, Gorey T, Ennis JT. Benign vs malignant breast disease: comparison of contrast-enhanced MR imaging and 99m-Tc-tetrofosmin scintimammography. Radiology 1997; 205: 214-220.
23. 23. Batista JF, Solano ME, Oliva JP, et al. Usefulness of 99m-Tc-tetrofosmin scintimammography in palpable breast tumours. Nucl Med Commun 1997; 18: 338-340.
24. 24. Markopoulos C, Sampalis F, Zerva C, et al. 99m-Tc-tetrofosmin imaging in breast tumours. Eur J Gynaecol Oncol 1998; 19: 163-166.
25. 25. Fenlon HM, Phelan N, Tierney S, Gorey T, Ennis JT. 99m-Tc-tetrofosmin scintigraphy as an adjunct to plain-film mammography in palpable breast lesions. Clin Radiol 1998; 53: 17-24.
26. 26. Arbab AS, Koizumi K, Toyama K, Araki T. Uptake of 99m-Tc-tetrofosmin, 99m-Tc-MIBI and thallium-201 in tumour cell lines. J Nucl Med 1996; 37: 1551-1556.
27. 27. Ballinger JR, Bannemann J, Boxen I, et al. Accumulation of 99m-Tc-tetrofosmin in breast tumour cells in vitro: role of multidrug resistance P-glycoprotein. J Nucl Med 1995; 36: 202.
28. 28. Ballinger JR, Hua HA, Berry BW, et al. 99m-Tc-MIBI as an agent for imaging P-glycoprotein-mediated multidrug resistance: in vitro and in vivo studies in rat breast tumour cell lines and its doxorubicin-resistant variant. Nucl Med Commun 1995; 16: 253.
29. 29. Ballinger JR, Banneman J, Boxen I, et al. 99m-Tc-tetrofosmin as a substrate for P-glycoprotein: in vivo studies in multidrug-resistant breast tumour cells. J Nucl Med 1996; 37: 1578-1581.
30. 30. De Jong M, Bernard BF, Breeman WAP, et al. Comparison of uptake of 99m-Tc-MIBI, 99m-Tc-tetrofosmin and 99m-Tc-Q12 into human breast cancer cell lines. Eur J Nucl Med 1996; 23: 1361-1366.
31. 31. Higley B, Smith FW, Smith T, et al. Technetium-99m-1,2-bis[bis(2-ethoxyethyl)phosphino]ethane: human biodistribution, dosimetry and safety of a new myocardial perfusion imaging agent. J Nucl Med 1993; 34: 222-227.
32. 32. Amano S, Inoue T, Tomiyoshi K, et al. In vivo comparison of PET and SPET radiopharmaceuticals in detecting breast cancer. J Nucl Med 1998; 39: 1424-1427.
33. 33. Fjeld JG, Erichsen K, Pfeffer PF, Clausen OPF, Rootwelt K. 99m-Tc-tetrofosmin for parathyroid scintigraphy: a comparison with 99m-Tc-MIBI. J Nucl Med 1997; 38: 831-834.
34. 34. Kostakoglu L, Uysal U, Özyar E, et al. A comparative study of 99m-Tc-MIBI and 99m-Tc-tetrofosmin single-photon tomography in the detection of nasopharyngeal carcinoma. Eur J Nucl Med 1997; 24: 621-628.
35. 35. Akcay MN, Akin Y, Karabag B, Özcan Ö, Ören D. 99m-Tc-tetrofosmin in breast carcinoma and axillary lymph node metastases: a comparative study with 99m-Tc-MIBI. Clin Nucl Med 1997; 22: 832-834.
36. 36. Ivancevic V, Marnitz S, Winzer KJ, et al. Intraindividual comparison of 99m-Tc-sestamibi and 99m-Tc-tetrofosmin in prone and supine scintimammography. Eur J Nucl Med 1996; 23: 1223.
37. 37. Schillaci O, Scopinaro F, Danieli R, et al. 99m-Tc-tetrofosmin scintimammography: accuracy in patients with suspicion of breast cancer and comparison with 99m-Tc-MIBI. Eur J Nucl Med 1996; 23: 1223.
38. 38. Mekhmandarov S, Sandbank J, Cohen M, Lelcuk S, Lubin E. 99m-Tc-MIBI scintimammography in palpable and nonpalpable breast lesions. J Nucl Med 1998; 39: 86-91.
39. 39. Tolmos J, Cutrone JA, Wang B, et al. Scintimammographic analysis of nonpalpable breast lesions previously identified by conventional mammography. J Natl Cancer Inst 1998; 90: 846-849.
40. 40. Schillaci O, Scopinaro F, Danieli R, et al. Technetium-99m-sestamibi scintimammography in patients with suspicious breast lesions: comparison of SPET and planar images in the detection of primary tumours and axillary lymph node involvement. Nucl Med Commun 1997; 18: 839-845.
41. 41. Aziz A, Hashmi R. Technetium-99 m MIBI scintimammography; SPET vs planar imaging. J Nucl Med 1999; 40: S248P.
42. 42. Buscombe JR, Cwikla JB, Thakrar DS, Hilson AJW. Uptake of 99m-Tc-MIBI related to tumour size and type. Anticancer Res 1997; 17: 1693-1694.
43. 43. Cwikla JB, Buscombe JR, Kelleher SM, et al. Poor specificity of scintimammography in primary breast cancer patients in the UK. J Nucl Med 1997; 38: 21-22.
44. 44. Taillefer R, Robidoux A, Lambert R, Turpin S, Laperriere J. 99m-Tc-MIBI prone scintimammography to detect primary breast cancer and axillary lymph node involvement. J Nucl Med 1995; 36: 1758-1765.
45. 45. Tolmos J, Khalkhali I, Vargas H, et al. Detection of axillary lymph node metastasis of breast carcinoma with technetium-99m sestamibi scintimammography. Am Surg 1997; 63: 850-853.
46. 46. Schillaci O, Scopinaro F, Danieli R, et al. Technetium-99 m sestamibi imaging in the detection of axillary lymph node involvement in patients with breast cancer. Anticancer Res 1997; 17: 1607-1610.
47. 47. Spnau A, Dettori G, Chiaramida P, et al. Tc-99m tetrofosmin (T) pinhole-SPET (P-SPET) in Breast Cancer (BC) axillary lymph node metastasis detection. J Nucl Med 1999; 40: S249